MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking.

MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Abstract Text:

Antibodies from malaria-exposed individuals can agglutinate merozoites released from Plasmodium schizonts, thereby preventing them from invading new erythrocytes. Merozoite coat proteins attached to the plasma membrane are major targets for host antibodies and are therefore considered important malaria vaccine candidates. Prominent among these is the abundant glycosylphosphatidylinositol (GPI)-anchored merozoite surface protein 1 (MSP1) and particularly its C-terminal fragment (MSP1(19)) comprised of two epidermal growth factor (EGF)-like modules. In this paper, we revisit the role of agglutination and immunity using transgenic fluorescent marker proteins. We describe expression of heterologous MSP1(19)'miniproteins' on the surface of Plasmodium falciparum merozoites. To correctly express these proteins, we determined that GPI-anchoring and the presence of a signal sequence do not allow default export of proteins from the endoplasmic reticulum to merozoite surface and that extra sequence elements are required. The EGFs are insufficient for correct trafficking unless they are fused to additional residues that normally reside upstream of this fragment. Antibodies specifically targeting the surface-expressed miniprotein can inhibit erythrocyte invasion in vitro despite the presence of endogenous MSP1. Using a line expressing a green fluorescent protein-MSP1 fusion protein, we demonstrate that one mode of inhibition by antibodies targeting the MSP1(19) domain is the rapid agglutinating of merozoites prior to erythrocyte attachment.

MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Molecular microbiology

VOLUME: 68

Page Numbers: 124-38

Journal Abbreviation:

ISSN: 1365-2958

DAY: 12

MONTH: Apr

YEAR: 2008

MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8712028

MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking.

AFFILIATION: The Walter and Eliza Hall Institute of Medical Research, Melbourne, Vic. 3050, Australia.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Mol Microbiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

MSP119 miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking Related Publications

• A rapid rosin-celloidin-paraffin method for embedding tissues.
• Alcohol Deranges Hepatic Lipid Metabolism via Altered Transcriptional Regulation.
• Alcohol and lipid metabolism.
• Analysis of visual field progression in glaucoma.
• Antibiotic sensitivity of staphylococci from noses of veterinary surgeons and farmers.
• Association of the aldehyde dehydrogenase 2 promoter polymorphism with alcohol consumption and reactions in an American Jewish population.
• CRALBP ligand and protein interactions.
• Carboxyethylpyrrole adducts, age-related macular degeneration and neovascularization.
• Evidence for a common role for the serine-type Plasmodium falciparum serine repeat antigen proteases: implications for vaccine and drug design.
• Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa.
• Genetic, age and light mediated effects on crystallin protein expression in the retina.
• Loss of sexual differentiation of rat hepatocytes in short-term culture.
• MSP1(19) miniproteins can serve as targets for invasion inhibitory antibodies in Plasmodium falciparum provided they contain the correct domains for cell surface trafficking.
• Metaphen and mercurochrome intravenously for sepsis.
• Metastasis in hamsters implanted with emulsified and with solid pieces of a mixed-cell sarcoma.
• More sensitive assay to detect drug-resistant HIV.
• Pathogenesis of alcoholic liver disease: newer mechanisms of injury.
• Retinal pigment epithelium lipofuscin proteomics.
• Targets of tyrosine nitration in diabetic rat retina.
• The cleansing of root canals.
• Towards a Vaccine against Plasmodium vivax Malaria.
• Truncation of Plasmodium berghei merozoite surface protein 8 does not affect in vivo blood-stage development.
• Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?